BridgeBio rises after study shows drug improving growth in children with dwarfism

Shares of BridgeBio Pharma BBIO.O rise 15.7% to $84.83 premarket

Co says its experimental therapy boosted growth rates in children with a rare genetic disorder that causes dwarfism, according to results from a late-stage study

Says the oral therapy, infigratinib, improved growth rate by 1.74 cm compared with placebo after 52 weeks in children with achondroplasia, a condition that causes disproportionately short stature

"We continue to see a clear path for BBIO to rapidly become a 4-product company (from 1 today), all of which have blockbuster potential," says brokerage Evercore ISI

As of last close, stock up 135.6% in the last 12 months